Mark Ator

Mark Ator is currently the AVP of Discovery DMPK at Parabilis Medicines. Previously, they held various leadership roles including VP of DMPK and Pharmacology at Psivant Therapeutics, and Senior Director of Molecular and Cellular Pharmacology at Teva Pharmaceuticals. Mark has also served as Executive Director of Preclinical Development at Roivant Sciences and VP of Preclinical Development at Oncopia Therapeutics. They have extensive experience in lead discovery and profiling from their tenure at Cephalon, Inc. Mark is pursuing a post-doctoral degree at the University of California, San Francisco, and holds a Ph.D. in Biochemistry from the University of Wisconsin-Madison, as well as a B.S. in Chemistry from the University of Virginia.